盐酸埃克替尼的药理学及临床研究进展

王雷 已出版文章查询
王雷
本平台内已出版文章查询
1 于佩瑶 已出版文章查询
于佩瑶
本平台内已出版文章查询
2 刘基巍 已出版文章查询
刘基巍
本平台内已出版文章查询
2

+ 作者地址

1116000,辽宁大连 大连市友谊医院肿瘤内科

21116000大连医科大学附属第一医院肿瘤内科


0
  • 摘要
  • 参考文献
  • 相关文章
  • 统计
非小细胞肺癌 NSCLC约占肺癌的80%~85%。晚期NSCLC主要以内科治疗为主,既往主要应用化疗,但疗效差。近年来,表皮生长因子受体酪氨酸激酶抑制剂 EGFR-TKI的应用为NSCLC的治疗提出了新的突破。盐酸埃克替尼作为一种国产的EGFR-TKI,其临床前期研究及其临床研究均显示其较好的安全性、耐受性和疗效,为晚期NSCLC治疗的新选择。

[1] Schlessinger J .Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.[J].Cell,2002(6):669-0.

[2] Herbst RS;Heymach JV;Lippman SM .Lung caner[J].New England Journal of Medicine,2008,359(13):1367-1380.

[3] Vincenzo Adamo;Tindara Franchina;Barbara Adamo;Nerina Denaro;Pietro Gambadauro;Giuseppe Chiofalo;Antonino Scimone;Nicola Caristi;Antonio Russo;Antonio Giordano .Gefitinib in lung cancer therapyClinical results, predictive markers of response and future perspectives[J].Cancer biology & therapy,2009(3):206-212.

[4] Giaccone G .Targeting HER1/EGFR in cancer therapy:experience with erlotinib[J].FUTURE ONCOLOGY,2005,1(04):449-460.

[5] Shigematsu H;Lin L;Takahashi T;Nomura M;Suzuki M;Wistuba II;Fong KM;Lee H;Toyooka S;Shimizu N;Fujisawa T;Feng Z;Roth JA;Herz J;Minna JD;Gazdar AF .Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.[J].Journal of the National Cancer Institute,2005(5):339-346.

[6] Tan,F.;Shen,X.;Wang,D.;Xie,G.;Zhang,X.;Ding,L.;Hu,Y.;He,W.;Wang,Y. .Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2012(2):177-182.

[7] 马丽,韩晓红,王帅,王建飞,石远凯.盐酸埃克替尼对肺癌细胞增殖和凋亡的影响[J].中华医学杂志,2012(36):2561-2564.

[8] 关忠民,陈笑艳,钟大放,王印祥.LC/MS/MS法测定比格犬血浆中埃克替尼及其在药动学研究中的应用[J].中国临床药理学与治疗学,2008(10):1158-1162.

[9] Guan ZM;Chen XY;Wang YX;Zhong DF .Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry[J].Rapid Communications in Mass Spectrometry: RCM,2008(14):2176-2184.

[10] 靳洪涛;王印祥;王爱平 等.Beagle犬单次和反复口服盐酸埃克替尼的毒性作用[J].中国药理学与毒理学杂志,2013,27(03):567.

[11] 谭芬来,张力,赵琼,刘东阳,胡云雁,刘勇,丁列明,胡蓓,王印祥.国家一类新药盐酸埃克替尼的药理与临床评价[J].中国新药杂志,2009(18):1691-1694.

[12] Liu D;Jiang J;Zhang L et al.Metabolite characterization of a novel anti-cancer agent,icotinib,in humans through liquid chro-matography/quadrupole time-of-flight tandem mass spectrometry[J].Rapid Communications in Mass Spectrometry,2011,25(15):2131-2140.

[13] Wang HP;Zhang L;Wang YX et al.Phase I trial of icotinib,a novel epidermal growth factor receptor tyrosine kinase inhibitor,in Chinese patients with non-small cell lung cancer[J].Chinese Medical Journal,2011,124(13):1933-1938.

[14] Zhao Q;Shentu J;Xu N;Yang G;Yao Y;Tan F;Liu D;Wang Y;Zhou J .Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2011(2):195-202.

[15] 张力,任冠军.盐酸埃克替尼治疗中国非小细胞肺癌患者40例的安全性、耐受性及疗效分析[J].中国新药杂志,2012(17):2051-2055.

[16] Zhang L;Jiang J;Liu DY.Icotinib, a potent and selective oral EGFR inhibitor, is well tolerated and active in patients with NSCLC:results from a phaseⅠ/Ⅱtrial[A].San Francisco,2009

[17] Sun Y;Shi Y;Zhang L et al.A randomized,double-blind phase Ⅲ study of icotinib versus gefitinib in patients with ad-vanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)[J].Journal of Clinical Oncology,2011,29(Suppl):a7522.

[18] REN Guan-jun,ZHAO Yuan-yuan,ZHU Yu-jia,XIAO Yi,XU Jia-sen,SHAN Bin,ZHANG Li.Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer[J].中华医学杂志(英文版),2011(01):19-25.

[19] 李曦,杨新杰,孙怡芬,秦娜,吕嘉林,吴羽华,张卉,张权,张树才.盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察[J].中华肿瘤杂志,2012(08):627-631.

[20] 农靖颖,秦娜,王敬慧,杨新杰,张卉,吴羽华,吕嘉林,张权,张树才.盐酸埃克替尼治疗晚期复发非小细胞肺癌的临床疗效[J].中国肺癌杂志,2013(05):240-245.

[21] 宋正波,余新民,蔡菊芬,邵岚,林宝钗,何春晓,张贝贝,张沂平.埃克替尼在晚期非小细胞肺癌EGFR状态明确的患者中的疗效分析[J].中国肺癌杂志,2013(03):138-143.

[22] Fukuoka M;Yano S;Giaccone G;Tamura T;Nakagawa K;Douillard JY;Nishiwaki Y;Vansteenkiste J;Kudoh S;Rischin D;Eek R;Horai T;Noda K;Takata I;Smit E;Averbuch S;Macleod A;Feyereislova A;Dong RP;Baselga J .Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.[J].Journal of Clinical Oncology,2003(12):2237-2246.

[23] Herbst RS .Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J].Seminars in Oncology,2003,30(01):30-38.

[24] Shepherd FA;Rodrigues Pereira J;Ciuleanu T;Tan EH;Hirsh V;Thongprasert S;Campos D;Maoleekoonpiroj S;Smylie M;Martins R;van Kooten M;Dediu M;Findlay B;Tu D;Johnston D;Bezjak A;Clark G;Santabarbara P;Seymour L .Erlotinib in previously treated non-small-cell lung cancer.[J].The New England journal of medicine,2005(2):123-132.

[25] Ji-Youn Han;Keunchil Park;Sang-We Kim;Dae Ho Lee;Hyae Young Kim;Heung Tae Kim;Myung Ju Ahn;Tak Yun;Jin Seok Ahn;Cheolwon Suh;Jung-Shin Lee;Sung Jin Yoon;Jong Hee Han;Jae Won Lee;Sook Jung Jo;Jin Soo Lee .First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung.[J].Journal of Clinical Oncology,2012(10):1122-1128.

[26] Mitsudomi T;Morita S;Yatabe .Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.[J].The lancet oncology,2010(2):121-128.

[27] Mok TS;Wu YL;Thongprasert S .Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.[J].The New England journal of medicine,2009(10):947-957.

[28] 何春晓,张贝贝,郑蕾,宋正波,邵岚,林宝钗,娄广媛,赵珺,张沂平.盐酸埃克替尼治疗31例晚期鳞状细胞肺癌临床疗效分析[J].中国新药杂志,2013(12):1430-1434.



期刊热词
  • + 更多
  • 字体大小